{name}
{subtitle}
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~15 mi. (Sutton, United Kingdom, +176 more cities)
facility
Royal Marsden Hospital Sutton-Surrey ( Site 2241)
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~15 mi. (Sutton, United Kingdom, +140 more cities)
facility
Royal Marsden NHS Trust ( Site 0693)
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~15 mi. (Sutton, United Kingdom, +137 more cities)
facility
Royal Marsden NHS Foundation Trust ( Site 1408)
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)
city
~15 mi. (Sutton, United Kingdom, +127 more cities)
facility
Royal Marsden Hospital ( Site 2904)
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
city
~15 mi. (Sutton, United Kingdom, +35 more cities)
facility
Royal Marsden NHS Trust ( Site 1063)
drug
favezelimab, +1 more drug